Yun J. Oh
Seoul, Republic of Korea
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Potent effect of the MDM2 inhibitor AMG232 on suppression of glioblastoma stem cells.
Journal: Cell death & disease
Published: January 29, 2018
Distinct predictive factors influence on achievement of early molecular response by frontline imatinib in chronic phase chronic myeloid leukemia.
Journal: Leukemia research
Published: September 06, 2014
Reversible Pulmonary Arterial Hypertension Associated with Dasatinib for Chronic Myeloid Leukemia.
Journal: Cancer research and treatment
Published: August 23, 2013
Prognostic factors for outcomes of allogeneic stem cell transplantation in chronic phase chronic myeloid leukemia in the era of tyrosine kinase inhibitors.
Journal: Hematology (Amsterdam, Netherlands)
Published: May 21, 2013
Predictive factors for successful imatinib cessation in chronic myeloid leukemia patients treated with imatinib.
Journal: American journal of hematology
Published: February 20, 2013
The long-term clinical implications of clonal chromosomal abnormalities in newly diagnosed chronic phase chronic myeloid leukemia patients treated with imatinib mesylate.
Journal: Cancer genetics
Published: June 11, 2012
Showing 1-8 of 8
Last Updated: 09/26/2026